Atara Biotherapeutics has filed a patent for a method of treating serous ovarian cancer by administering an anti-activin-A antibody to the subject. The antibody binds to human activin-A and is combined with the chemotherapeutic compound capecitabine. The invention also includes methods of identifying subjects for treatment based on specific biomarkers or angiogenic factors. GlobalData’s report on Atara Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Atara Biotherapeutics, CAR-T cell-based compositions was a key innovation area identified from patents. Atara Biotherapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating serous ovarian cancer with anti-activin-a antibody
A recently filed patent (Publication Number: US20230201231A1) describes a method for treating serous ovarian cancer using an anti-activin-A antibody. The method involves administering a therapeutically effective amount of the antibody to a subject in need. The antibody is designed to bind to human activin-A, a protein involved in cancer progression.
The anti-activin-A antibody described in the patent comprises a light chain variable domain sequence and a heavy chain variable domain sequence. The light chain variable domain sequence can be selected from a group of amino acid sequences or polynucleotide sequences disclosed in the patent. Similarly, the heavy chain variable domain sequence can be selected from a group of amino acid sequences or polynucleotide sequences disclosed in the patent. Alternatively, the antibody can consist of the light chain variable domain sequence and the heavy chain variable domain sequence.
In both claims, the method for treating serous ovarian cancer involves administering the anti-activin-A antibody along with a chemotherapeutic compound. In the first claim, the chemotherapeutic compound specified is capecitabine, while in the second claim, it is a doxorubicin lipid complex.
Serous ovarian cancer is a subtype of ovarian cancer that accounts for a significant proportion of cases. Activin-A has been implicated in the progression and development of serous ovarian cancer. By targeting activin-A with the anti-activin-A antibody, the method described in the patent aims to provide a potential treatment option for patients with serous ovarian cancer.
The use of the specified chemotherapeutic compounds, capecitabine and doxorubicin lipid complex, in combination with the anti-activin-A antibody suggests a potential synergistic effect in treating serous ovarian cancer. However, further research and clinical trials would be necessary to validate the efficacy and safety of this method.
Overall, the patent claims describe a method for treating serous ovarian cancer using an anti-activin-A antibody that specifically binds to human activin-A. The inclusion of different chemotherapeutic compounds in the treatment regimen provides potential options for personalized medicine in the management of serous ovarian cancer.
To know more about GlobalData’s detailed insights on Atara Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
